VICENTE VALERO to Antibodies, Monoclonal, Humanized
This is a "connection" page, showing publications VICENTE VALERO has written about Antibodies, Monoclonal, Humanized.
Connection Strength
0.357
-
T-DM1 Activity in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancers That Received Prior Therapy With Trastuzumab and Pertuzumab. J Clin Oncol. 2016 10 10; 34(29):3511-3517.
Score: 0.065
-
Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancer. Cancer. 2014 Jul 01; 120(13):1932-8.
Score: 0.055
-
Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer. J Clin Oncol. 2014 Mar 10; 32(8):735-44.
Score: 0.054
-
Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer. Cancer. 2012 May 01; 118(9):2385-93.
Score: 0.046
-
Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. J Clin Oncol. 2011 Jan 10; 29(2):149-56.
Score: 0.043
-
Neoadjuvant systemic therapy for breast cancer: an overview and review of recent clinical trials. Expert Opin Pharmacother. 2005 Aug; 6(9):1477-91.
Score: 0.030
-
Neoadjuvant Pertuzumab-containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER-2/neu-positive Breast Cancer: A Retrospective, Single Institution Experience. Clin Breast Cancer. 2018 12; 18(6):e1283-e1288.
Score: 0.018
-
Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Res. 2011 Jun 15; 13(3):R67.
Score: 0.011
-
Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patients. Br J Cancer. 2010 Oct 26; 103(9):1331-4.
Score: 0.011
-
Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol. 2010 Jan 20; 28(3):453-9.
Score: 0.010
-
Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol. 2005 Nov 01; 23(31):7820-6.
Score: 0.008
-
Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol. 2001 May 15; 19(10):2587-95.
Score: 0.006